Skip to content

Ceftibuten

DRUG8 trials

Sponsors

IRCCS Burlo Garofolo, Basilea Pharmaceutica, Qpex Biopharma, Inc., Pfizer

Conditions

Bacterial InfectionsDrug-Drug Interaction (DDI)FDCHealthyHealthy VolunteerHealthy VolunteersPharmacokineticsPyelonephritis

Phase 1

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
CompletedNCT05488678
Basilea PharmaceuticaPharmacokinetics
Start: 2022-10-12End: 2023-11-23Updated: 2025-12-08
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
CompletedNCT05527834
Basilea PharmaceuticaPharmacokinetics
Start: 2022-09-13End: 2023-02-10Updated: 2025-12-08
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
CompletedNCT06079775
Qpex Biopharma, Inc.Bacterial Infections
Start: 2024-01-30End: 2025-01-05Updated: 2025-12-12
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
CompletedNCT06157242
Qpex Biopharma, Inc.Bacterial Infections
Start: 2024-11-10End: 2025-03-31Updated: 2025-05-14
To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults
CompletedNCT06593054
PfizerHealthy
Start: 2024-07-29End: 2024-10-11Updated: 2025-05-21
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
CompletedNCT06665555
Basilea PharmaceuticaHealthy Volunteers, Pharmacokinetics
Start: 2024-11-04End: 2025-03-17Updated: 2026-01-23
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RecruitingNCT06733675
Basilea PharmaceuticaDrug-Drug Interaction (DDI), FDC, Healthy Volunteer +2
Start: 2025-01-07End: 2026-12-30Target: 96Updated: 2026-07-09

Phase 3

Related Papers